Innovations in clinical trial design with ctDNA MRD
With 20 peer-reviewed publications and over 60 abstracts and presentations, Signatera has been incorporated into a growing number of ongoing clinical trials and pharma partnerships, including for registrational studies with potential for CDx development.
Learn about the latest advances in leveraging bespoke ctDNA testing in clinical trials and discover improvements to clinical trial design with Signatera including stratifying and enriching for patients at the highest risk of recurrence and most likely to respond to therapy for clinical enrollment. Additionally, treatment response monitoring can enable the prediction of clinical outcomes as early as 6 weeks into treatment, unlock use as a surrogate endpoint, and accelerate clinical development.
Topics include:
- Latest clinical data from 2021 publications and presentations (including ESMO, ESMO GI, Nature publications, and others)
- Applications of Signatera in clinical trial design to maximize trial success and accelerate time to data readout
- Advantages of a personalized, tumor-informed ctDNA assay for molecular residual disease detection
